Close Menu

NEW YORK – Celyad Oncology said on Tuesday that it is partnering with Merck to conduct a study in which its investigational CAR T-cell therapy, CYAD-101, will be evaluated in combination with Merck's anti-PD-1 therapy pembrolizumab (Keytruda) in certain advanced colorectal cancer patients.

In the Phase Ib Keynoted-B79 trial, refractory and metastatic colorectal cancer patients will receive FOLFIRI as preconditioning chemotherapy before receiving CYAD-101 and pembrolizumab, and their tumors must be microsatellite stable or mismatch repair proficient.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.


Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.